The following is an excerpt of a press release from Bayer. Read the press release in its entirety here.
Bayer will present new data highlighting clinical outcomes from its hemophilia A portfolio, which include long-term data from the PROTECT VIII investigational study evaluating use of Jivi® antihemophilic factor (recombinant) PEGylated-aucl. These data will be presented during the XXVII Congress of the International Society on Thrombosis and Haemostasis, taking place July 6 to 10, 2019, in Melbourne, Australia.
“For over 30 years, we’ve had a steadfast focus on looking for new ways to understand how patients can benefit from our portfolio of hemophilia A therapies, and these data bring to light important insights we believe can inform treatment strategies for patients,” said Aleksandra Vlajnic, M.D., Vice President of Bayer Medical Affairs. “We’re committed to contributing to future advancements for the hemophilia A community.”
Among the six abstracts of antihemophilic factor (recombinant) PEGylated-aucl, Bayer will present data on efficacy and safety, target joint resolution and patient-reported outcomes from patients exiting the long-term PROTECT VIII Extension Study.
All abstracts regarding Bayer’s portfolio therapies featured at the ISTH 2019 Congress are listed in the full press release from Bayer. Read the press release in its entirety.
